Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (25)	2/9/1999 1:01:00 AM
From: margie	Respond to of 438

This past weekend Baron's reported that Mills Value Adviser purchased an additional 140,618 shares of enmd at $25.26 to $29.97 between 1/11 to 1/27. They now have a 7.3% stake, up from 6.1% in January. I'm sure they are real happy. Interesting news about the "mystery" protein and quite a coup for gzmo, the new oncology division of Genzyme.....sigh As usual, Richard, looks like you're right about enmd.

To: scaram(o)uche who wrote (25)	2/9/1999 9:45:00 PM
From: StockMiser	Read Replies (3) \| Respond to of 438

Rick - Boy I wish I had followed your advice and shorted ENMD. Have you seen the latest news? Bristal Myers just "stepped aside" from any further involvement with angiostatin. The language in the release is very...harsh, imho. Here is tis... Bristol-Myers bows out of cancer protein project By Janet Haney, CBS MarketWatch Last Update: 8:29 PM ET Feb 9, 1999 Movers & Shakers PRINCETON, N.J. (CBS.MW) -- Bristol-Myers Squibb and EntreMed said Tuesday the companies have re-evaluated a research agreement concerning Angiostatin protein, resulting in Bristol-Myers' stepping aside from further development of the cancer-therapy protein for now. Under the agreement, Rockville, Md.-based EntreMed (ENMD) is now responsible for all upcoming work on the molecule. Bristol-Myers Squibb (BMY) has the option to "reassume" development and marketing once proof that the protein meets its criteria for clinical trials becomes clear. Angiostatin is an antiangiogenic molecule being studied as a possible cancer therapy. Antiangiogenesis research includes the prevention of abnormal blood-vessel growth related to a variety of diseases. "At this time, Angiostatin protein in its present form does not meet our criteria for molecules that advance to clinical trials," Robert A. Kramer, vice president of oncology drug discovery for Bristol-Myers, said in a press release. "We have chosen to direct our resources to other programs in our broad oncology pipeline. We continue, however, to view antiangiogenesis as an important and viable target in the spectrum of oncology research," he added. ---------------------- Given the research inconsistencies of endiostatin, and Folkman's recent move, I think the writing is on the wall. Entremed could lose 10 points over the next couple weeks, imho.